Clinical trials

Dassault Systemes buying Medidata in $5.8 billion deal

Dassault Systemes CEO Bernard Charles speaks behind a podium.
Dassault Systemes CEO Bernard Charles. Photo: Vincent Isore/IP3/Getty Images

Dassault Systemes, a French maker of industrial software and technology, is buying New York-based health data provider Medidata in a deal worth $5.8 billion.

The bottom line: Medidata registered a $52 million profit last year on $636 million of revenue, but Dassault is betting that more pharmaceutical and medical device companies will use Medidata's software to help their products clear clinical trials. More than 1,000 health care companies already use Medidata for clinical trial work.

How the Pfizer-Alzheimer's story may have been overblown

In this image, a man and a woman walk past a large metal logo for Pfizer
The Pfizer logo. Photo: Spencer Platt/Getty Images

The Washington Post's story this week on how Pfizer opted out of pursuing a link between one of its blockbuster drugs and Alzheimer's prevention may have been overblown, Derek Lowe writes in Science Translational Medicine's blog.

The state of play: Undertaking an Alzheimer's trial is a huge endeavor, Lowe argues, and is both risky and expensive. "The clinical success rate for Alzheimer's trials is arguably zero per cent," he writes.